OTC switch approval in Finland for Sitavig® 50mg

Vectans Pharma is proud to announce that Fimea (Finnish Medicines Agency) has granted OTC status to its Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, as a one-per-episode treatment.

"I am pleased to share the news of Sitavig® receiving OTC status in Finland with our partner, Navamedic ASA . This achievement reflects our collective effort and provides a unique opportunity to offer patients access to an innovative treatment," states Vectans Pharma's Director of Regulatory and Industrial Affairs, Jonathan Cohen.

Following Italy and France, Finland is now the third country to grant OTC status upon Lauriad® Aciclovir, while we await further agreements in our global switch projects.


Exclusive agreement with the Menarini group and Berlin Chemie

Vectans Pharma is delighted to collaborate with the Menarini group and Berlin Chemie for the commercialization of Sitavig® in Italy and Austria.

Season's greetings 2023

Season's greetings

Vectans Pharma wishes you a happy and healthy New Year!

New talent joins the team

Welcome to Medine Kockan, our new talent!

We are thrilled to welcome Medine Kockan as our new intern in Marketing and Strategic Innovation!

She will contribute to the many projects of our team. We are excited for her to participate in our continued growth!

OTC switch approval for SitavigFrance

OTC switch approval for Sitavig® 50 mg in France

Vectans pharma is proud to announce that its one-per-episode Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, has received the approbation of the ANSM for OTC commercialization in France. Issued from Lauriad technology, SITAVIG ensures an optimum and efficient localized concentration of acyclovir directly at the disease site.
A big step for Vectans , but also for the many patients in France prone to recurrent

Lauriad technology

Lauriad® technology in pictures

Because changing the way medicines are delivered can improve patient’s life drastically. With Lauriad® we are committed to optimizing the existing therapeutic offer, bringing out new « best-in-disease » drugs.


230 Bureaux de la colline
92213 Saint-Cloud